Journal of Shanghai Jiao Tong University (Medical Science) ›› 2024, Vol. 44 ›› Issue (3): 379-384.doi: 10.3969/j.issn.1674-8115.2024.03.011
• Review • Previous Articles
FAN Qiang(), WU Guangbo, ZHAO Jinbo, ZHENG Lei, LUO Meng()
Received:
2023-10-23
Accepted:
2023-12-08
Online:
2024-03-28
Published:
2024-04-29
Contact:
LUO Meng
E-mail:13472665251@163.com;luosh9hospital@sina.com
Supported by:
CLC Number:
FAN Qiang, WU Guangbo, ZHAO Jinbo, ZHENG Lei, LUO Meng. Research progress in pathophysiological and molecular mechanism changes during decompensated phase of portal hypertension in liver cirrhosis[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(3): 379-384.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2024.03.011
1 | MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437, 1437.e1-1437.e9. |
2 | BAJAJ J S, O'LEARY J G, LAI J C, et al. Acute-on-chronic liver failure clinical guidelines[J]. Am J Gastroenterol, 2022, 117(2): 225-252. |
3 | TREBICKA J, FERNANDEZ J, PAPP M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology[J]. J Hepatol, 2020, 73(4): 842-854. |
4 | GUSTOT T, FERNANDEZ J, GARCIA E, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis[J]. Hepatology, 2015, 62(1): 243-252. |
5 | BERZIGOTTI A. Advances and challenges in cirrhosis and portal hypertension[J]. BMC Med, 2017, 15(1): 200. |
6 | BERNARDI M, CARACENI P. Novel perspectives in the management of decompensated cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(12): 753-764. |
7 | BOSCH J, GROSZMANN R J, SHAH V H. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments[J]. J Hepatol, 2015, 62(1 Suppl): S121-S130. |
8 | AMIN A A, ALABSAWY E I, JALAN R, et al. Epidemiology, pathophysiology, and management of hepatorenal syndrome[J]. Semin Nephrol, 2019, 39(1): 17-30. |
9 | BOSCH J, BERZIGOTTI A, GARCIA-PAGAN J C, et al. The management of portal hypertension: rational basis, available treatments and future options[J]. J Hepatol, 2008, 48(Suppl 1): S68-S92. |
10 | BOSCH J, IWAKIRI Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models[J]. Hepatol Int, 2018, 12(Suppl 1): 1-10. |
11 | CERINI F, VILASECA M, LAFOZ E, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats[J]. J Hepatol, 2016, 64(4): 834-842. |
12 | GRACIA-SANCHO J, MARRONE G, FERNÁNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 221-234. |
13 | GRACIA-SANCHO J, RUSSO L, GARCÍA-CALDERÓ H, et al. Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver[J]. Gut, 2011, 60(4): 517-524. |
14 | ALBILLOS A, LLEDÓ J L, ROSSI I, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function[J]. Gastroenterology, 1995, 109(4): 1257-1265. |
15 | NAVASA M, CHESTA J, BOSCH J, et al. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function[J]. Gastroenterology, 1989, 96(4): 1110-1118. |
16 | BELLIS L, BERZIGOTTI A, ABRALDES J G, et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis[J]. Hepatology, 2003, 37(2): 378-384. |
17 | SCHWABL P, BRUSILOVSKAYA K, SUPPER P, et al. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats[J]. Sci Rep, 2018, 8(1): 9372. |
18 | BOSCH J, GRACIA-SANCHO J, ABRALDES J G. Cirrhosis as new indication for statins[J]. Gut, 2020, 69(5): 953-962. |
19 | POSE E, SOLÀ E, LOZANO J J, et al. Treatment with simvastatin and rifaximin restores the plasma metabolomic profile in patients with decompensated cirrhosis[J]. Hepatol Commun, 2022, 6(5): 1100-1112. |
20 | BOIKE J R, THORNBURG B G, ASRANI S K, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1636-1662.e36. |
21 | SHARPTON S R, LOOMBA R. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC[J]. Hepatology, 2023, 78(6): 1896-1906. |
22 | WIEST R, GROSZMANN R J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough[J]. Hepatology, 2002, 35(2): 478-491. |
23 | PIZCUETA P, PIQUÉ J M, FERNÁNDEZ M, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition[J]. Gastroenterology, 1992, 103(6): 1909-1915. |
24 | TURCO L, REIBERGER T, VITALE G, et al. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension[J]. Liver Int, 2023, 43(6): 1183-1194. |
25 | RADWAN H, IBRAHIM O, BADRA G, et al. Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites[J]. Eur Rev Med Pharmacol Sci, 2022, 26(18): 6608-6619. |
26 | ALUKAL J J, JOHN S, THULUVATH P J. Hyponatremia in cirrhosis: an update[J]. Am J Gastroenterol, 2020, 115(11): 1775-1785. |
27 | ANGELI P, GARCIA-TSAO G, NADIM M K, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document[J]. J Hepatol, 2019, 71(4): 811-822. |
28 | POZZI M, CARUGO S, BOARI G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites[J]. Hepatology, 1997, 26(5): 1131-1137. |
29 | ENGELMANN C, CLÀRIA J, SZABO G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. J Hepatol, 2021, 75(Suppl 1): S49-S66. |
30 | HÄUSSINGER D, SCHLIESS F. Pathogenetic mechanisms of hepatic encephalopathy[J]. Gut, 2008, 57(8): 1156-1165. |
31 | JIMÉNEZ W, RODÉS J. Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis[J]. Gastroenterology, 1994, 107(4): 1201-1203. |
32 | GANDHI K D, TAWEESEDT P T, SHARMA M, et al. Hepatopulmonary syndrome: an update[J]. World J Hepatol, 2021, 13(11): 1699-1706. |
33 | ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74(3): 670-685. |
34 | CLÀRIA J, STAUBER R E, COENRAAD M J, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. |
35 | WANG R, TANG R Q, LI B, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cell Mol Immunol, 2021, 18(1): 4-17. |
36 | BETRAPALLY N S, GILLEVET P M, BAJAJ J S. Gut microbiome and liver disease[J]. Transl Res, 2017, 179: 49-59. |
37 | WIEST R, CADELINA G, MILSTIEN S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats[J]. Hepatology, 2003, 38(6): 1508-1515. |
38 | TAZI K A, MOREAU R, HERVÉ P, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling[J]. Gastroenterology, 2005, 129(1): 303-314. |
39 | WREE A, MCGEOUGH M D, INZAUGARAT M E, et al. NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice[J]. Hepatology, 2018, 67(2): 736-749. |
40 | SZABO G, PETRASEK J. Inflammasome activation and function in liver disease[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(7): 387-400. |
41 | ADEBAYO D, MORABITO V, ANDREOLA F, et al. Mechanism of cell death in acute-on-chronic liver failure: a clinico-pathologic-biomarker study[J]. Liver Int, 2015, 35(12): 2564-2574. |
42 | LI W B, DENG M H, LOUGHRAN P A, et al. LPS induces active HMGB1 release from hepatocytes into exosomes through the coordinated activities of TLR4 and caspase-11/GSDMD signaling[J]. Front Immunol, 2020, 11: 229. |
43 | ENGELMANN C, SHEIKH M, SHARMA S, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure[J]. J Hepatol, 2020, 73(1): 102-112. |
44 | ENGELMANN C, ADEBAYO D, ORIA M, et al. Recombinant alkaline phosphatase prevents acute on chronic liver failure[J]. Sci Rep, 2020, 10(1): 389. |
45 | BROZ P, DIXIT V M. Inflammasomes: mechanism of assembly, regulation and signalling[J]. Nat Rev Immunol, 2016, 16(7): 407-420. |
46 | PRAKTIKNJO M, SCHIERWAGEN R, MONTEIRO S, et al. Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosis[J]. Gut, 2021, 70(9): 1799-1800. |
47 | GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58(5): 1836-1846. |
48 | DOMENICALI M, BALDASSARRE M, GIANNONE F A, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis[J]. Hepatology, 2014, 60(6): 1851-1860. |
49 | ALCARAZ-QUILES J, CASULLERAS M, OETTL K, et al. Oxidized albumin triggers a cytokine storm in leukocytes through P38 mitogen-activated protein kinase: role in systemic inflammation in decompensated cirrhosis[J]. Hepatology, 2018, 68(5): 1937-1952. |
50 | BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives[J]. Gut, 2020, 69(6): 1127-1138. |
[1] | LI Qianyu, GUO Wenyun, QIAN Yifei, LI Songling, ZHU Zijun, LIU Yanfeng. Study on the significance and mechanism of ASGR1 in hepatocellular carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1107-1114. |
[2] | SHI Cuicui, ZHANG Jie, HUANG Heming, SANG Yuer, LI Guangming. Clinical analysis of insulin resistance in liver cirrhosis patients [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 188-193. |
[3] | HU Chanchan, FAN Yi, XU Yuan, HU Zhijian, ZENG Yiming. Lipid metabolism and lung cancer: emerging roles in occurrence, progression, diagnosis and treatment [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(12): 1766-1771. |
[4] | Lei XIONG, Qian YI, Ming-fang XU, Jian CHEN. Expression and prognosis analysis of MRPL12 in lung adenocarcinoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1033-1040. |
[5] | ZHENG Lei, LIN Jia-yun, ZHANG Chi-hao, ZHAO Zhi-feng, LI Hong-jie, QI Xiao-liang, HUO Hai-zhong#, LUO Meng#. Experimental study of superior mesenteric artery remodeling in cirrhotic rats with portal hypertension [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1340-1346. |
[6] | WANG Jun-ying1, LI Xin1, YIN Ting-yu2, LIU Jia2, WANG Xiao-dong3, ZHONG Hua1. Effects of bone marrow mesenchymal cells immune thrombocytopenia patients on the biological behaviors of megakaryocytes [J]. , 2018, 38(6): 616-. |
[7] | ZHAO Dan, MAO Hua, HUANG Chun-chi, et al. Study on noninvasive prediction indicators for incidence of esophageal varices of patients with liver cirrhosis caused by hepatitis B [J]. , 2015, 35(3): 386-. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||